semaglutide: tirzepatide drives more weight loss (~20% vs ~15%), but semaglutide has the longer track record and in 2026 there's now a third oral option
Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis
GLP-1 receptor agonists reduce inflammatory cytokines, improve insulin resistance, aid gut health, and help lower the chronic inflammation that drives many forms of arthritis, as well as metabolic and heart diseases. Are GLP-1 medications safe, and who should not use them
Nausea (44%), diarrhoea (30%), vomiting (24%), and constipation (24%)
Citalopram should be used with caution in patients with severe renal impairment
Many patients report noticeable improvements in energy levels, sleep quality, and body composition within 1-3 months of consistent use